Request Demo

Last update 08 May 2025

Pelvic Lipomatosis

Last update 08 May 2025

Basic Info

Synonyms

Pelvic Lipomatosis, Pelvic lipomatosis, Pelvic lipomatosis (morphologic abnormality)

+ [1]

Introduction

A neoplastic process characterized by a diffuse poorly circumscribed overgrowth of adipose tissue in the pelvic region. Clinical presentation includes complaints of back and abdominal pain, urinary frequency, perineal pain and constipation. It predominately affects black males.

Clinical Trials associated with Pelvic Lipomatosis

ChiCTR2500096973

/ SuspendedNot ApplicableIIT

Construction and validation of an artificial intelligence-assisted diagnostic system for pelvic lipomatosis based on radiomics

Start Date11 Feb 2025

Sponsor / Collaborator

Peking University First Hospital

ChiCTR-DDT-11001515

/ CompletedPhase 1IIT

Measuring diagnostic accuracy of imaging patterns in pelvic lipomatosis: a retrospective study in 32 clinical proved cases

Start Date01 Jan 2002

Sponsor / Collaborator

Peking University First Hospital

100 Clinical Results associated with Pelvic Lipomatosis

100 Translational Medicine associated with Pelvic Lipomatosis

0 Patents (Medical) associated with Pelvic Lipomatosis

299

Literatures (Medical) associated with Pelvic Lipomatosis

01 Dec 2024·Journal of Surgical Case Reports

Pelvic lipomatosis—a rare diagnosis and a challenging management: a case report and literature review

Article

Author: Ismail, Taha ; Al Jalham, Khalid ; Al-Jassim, Fatima A ; Alabassi, Kholoud ; Ata, Yaser M ; Albakr, Ahmed

AbstractPelvic lipomatosis (PL) involves nonmalignant excess fat growth in perirectal and perivesical areas, gaining recognition over three decades. This review addresses its clinicopathological aspects amid controversies, emphasizing the need for a comprehensive examination of current literature. This report outlines a 42-year-old man’s diagnostic journey for persistent urological symptoms, ultimately identified as PL. PL, if untreated, adversely impacts the urinary system, affecting kidney function and causing systemic complications. Management involves accurate diagnosis through radiological methods and surgical intervention, aiming to alleviate symptoms and enhance affected individuals’ quality of life.

18 Oct 2024·Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

[Efficacy of coated metal ureteral stent in the treatment of pelvic lipomatosis induced hydronephrosis].

Article

Author: Wan, Chunyan ; Tang, Xinwei ; Hu, Hao ; Xu, Tao ; Lai, Jinhui ; Wang, Mingrui ; Wang, Qi ; Xu, Kexin

To investigate the initial experience of coated metal ureteral stent (CMUS) for treatment of pelvic lipomatosis induced hydronephrosis (PLH). The clinical and follow-up data of 8 patients who were diagnosed as PLH treated with CMUS in Peking University People's Hospital from August 2018 to February 2021 were retrospectively analyzed. Inclusion criteria included: Imaging evidence of excessive adipose tissue around the bladder in the pelvic cavity, bladder elevation in an "inverted pear shape", and bladder wall thickening; Cystoscopy indicated follicular hyperplasia of bladder mucosa and biopsy pathology indicated glandular cystitis; Unilateral or bilateral hydronephrosis and ureteromegaly. Exclusion criteria included: Ureteral atresia; Recurrent obstruction of the bladder outlet. Preoperative baseline data included age, gender, serum creatinine, pelvis width and ureteric stent symptoms questionnaire (USSQ) score. Intraoperative data included the location and length of ureteral stenosis observed by retrograde urography. Postoperative follow-up data included serum creatinine, pelvis width, and USSQ score. In the study, 8 patients (11 sides) with PLH were all male, with an average age of (38.7±8.6) years. Unilateral hydronephrosis was found in 5 cases and bilateral hydronephrosis in 3 cases. Preoperative mean serum creatinine was (90.0±10.3) μmol/L, and the mean renal pelvis width was (3.0±1.5) cm. The lower ureteral stricture was found in all cases, and the mean stricture length was (1.9±0.9) cm. Before operation, 3 patients had ureteral Double-J stents, with USSQ scores of 97.0, 68.0 and 100.0, respectively. Five patients underwent retrograde CMUS stenting, and 3 patients retrograde and antegrade. At the last follow-up, the average serum creatinine was (82.0±11.1) μmol/L and the mean renal pelvis width was (1.9±0.5) cm, which were significantly lower than those before operation (t=3.12, P=0.02; t=3.23, P=0.02). In the 3 patients with Double-J stent before surgery, the USSQ scores were 87.0, 62.0 and 89.0, respectively, which were significantly improved after CMUS stenting. The average follow-up time was (10.0±6.3) months. During the follow-up, 1 patient developed CMUS related symptoms, and no stent-associated infection and stent encrustation were found. In one case, the stent migrated to the bladder 3 months after operation, and the hydronephrosis disappeared after 3 months follow-up. CMUS stenting for treatment of PLH has certain efficacy and safety, which can explore a new therapeutic method for the long-term treatment of PLH.

18 Oct 2024·Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

[Etiological analysis of hydronephrosis in adults: A single-center cross-sectional study].

Article

Author: He, Yuhui ; Xu, Yangyang ; Huang, Yanbo ; Wang, Haiju ; Li, Zhihua ; Guan, Hua ; Chen, Silu ; Li, Xuesong ; Wu, Yucai

OBJECTIVETo investigate the etiological distribution of hydronephrosis caused by upper urinary tract obstruction in adult patients and to improve the diagnostic accuracy for this condition.METHODSThe clinical information of adult patients with newly diagnosed hydronephrosis in Upper Urinary Tract Repair Outpatient Clinic of Peking University First Hospital from May 2020 to May 2021 were prospectively and continuously collected. Patients with ureteral calculi or upper urinary tract tumor were excluded. A total of 767 patients were involved. The underlying causes of upper urinary tract obstruction were identified by senior urological surgeons according to symptoms, medical history, physical examination, and a range of diagnostic imaging techniques including ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), retrograde pyelography, antegrade pyelography, radionuclide renogram and ureteroscopy.RESULTSAmong the 767 patients, 359(46.8%) were male and 408(53.2%) were female. The median age of these patients was 37 years (range, 14-84 years). Hydronephrosis was observed at left-sided in 357 cases(46.6%), right-sided in 251 cases(32.7%), and bilateral in 159 cases(20.7%). The causes of hydronephrosis were classified as follows: (1) Non-iatrogenic factors were found in 464 cases (60.5%). These included urinary malformations in 355 cases(76.5%), infection in 29 cases(6.3%), pelvic lipomatosis and/or cystitis glandularis in 23 cases(5.0%), ureteral endometriosis in 18 cases(3.9%), retroperitoneal fibrosis in 15 cases(3.2%), trauma in 7 cases(1.5%) and other non-iatrogenic factors in 12 cases(2.6%). Some of these patients had multiple non-iatrogenic causes. Among the 355 cases with urinary system malformations, 252 cases (71.0%) had ureteropelvic junction obstruction. (2) Iatrogenic ureteral injuries accounted for 210 cases (27.4%), including 112 cases(53.3%) of urological surgical injuries, 51 cases(24.3%) of radiotherapy for malignant tumor related injuries, 34 cases(16.2%) of gynecological and obstetrical surgical injuries, and 13 cases(6.2%) of general surgical injuries. (3) The cause of hydronephrosis remained unknown in 93 cases(12.1%).CONCLUSIONHydronephrosis in adults due to upper urinary tract obstruction has a diverse range of causes, with urinary malformations and iatrogenic ureteral injuries being significant contributors. Urological surgeon involved in upper urinary tract reconstruction should be familiar with these potential causes to facilitate accurate diagnosis and effective treatment.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Pelvic Lipomatosis

Basic Info

Related

Analysis